Relative efficacy of the opioid antagonist, naltrexone, on the initiation and promotion phases of rat mammary carcinogenesis

Anticancer Research

Volumn 16, Issue 4 A, 1996, Pages 1893-1898

  Koo, Kwok L ^a   Tejwani, Gopi A ^a   Abou Issa, Hussein ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Breast cancer; Mammary tumors; Naltrexone; Opioid peptides

Indexed keywords

NALTREXONE; OPIATE ANTAGONIST;

ANIMAL EXPERIMENT; ARTICLE; BREAST CARCINOGENESIS; BREAST TUMOR; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; NONHUMAN; PRIORITY JOURNAL; RAT;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; ANTICARCINOGENIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; DIET; FEMALE; MAMMARY NEOPLASMS, EXPERIMENTAL; NALTREXONE; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS;

EID: 0029758725     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Zagon IS, McLaughlin PJ, Goodman SR and Rhodes RE: Opioid receptors and endogenous opioids in diverse human and animal cancers. J Natl Cancer Inst 79: 1059-1064, 1987.
2. Zagon IS, Goodman SR and McLaughlin PJ: Demonstration and characterization of zeta (ζ), a growth-related opioid receptor, in a neuroblastoma cell line. Brain Res 511: 181-186, 1990.
3. Thomas GL, Szucs M, Mamone JY, Bem WT, Rush MD. Johnson FE and Coscia CJ: Sigma and opioid receptors in human brain tumors. Life Sci 46: 1279-1286, 1990.
4. Bem WT, Thomas GE, Mamone JY, Homan SM, Levy BK, Johnson FE and Coscia CJ: Overexpression of a receptors in nonneural human tumors. Cancer Res 51: 655 6562, 1991.
5. Bostwick DG, Null WE, Holmes D, Weber E, Barchas JD and Bensch KG: Expression of opioid peptides in tumors. The New England J of Med 317: 1439-1443, 1987.
6. Ottesen B, Jacobsen K, Andresen A, Ulrichsen H, Thomsen HK and Larsson L-I: Opioid-like immunoreactants in human cervical cancer. Gyn Oncol 36: 250-255, 1990.
7. Scopsi L, Balslev E, Brunner N, Poulsen HS, Andersen J, Rank F and Larsson L-I: Immunoreactive opioid peptides in human breast cancer. Amer J of Pathol 134: 473479, 1989.
8. Chatikhine VA, Chevrier A, Chauzy C. Kwval C, D'Anjou J, Girard N and Delpech B: Expression of opioid peptides in cells and stroma of human breast cancer and adenofibromas. Cancer Lett 77: 51-56, 1994.
9. Roth KA, Bensch KG and Huffman AR: Characterization of opioid peptides in human thyroid medullary carcinoma. Cancer 59: 1594-1598, 1987.
10. Iishi H, Tatsuta M, Baba M, Okuda S and Taniguchi H: Enhancement by methionine enkephalin of colon carcinogenesis induced by azoxymethane. Cancer Res 51: 785-788, 1991.
11. Kikuchi Y, Kita T, Miyauchi M, Kizawa I, Oomori K and Kato K: Effects of Naloxone on human ovarian cancer cell growth in vitro and in vivo. Jpn J Cancer Res 78: 519-525, 1987.
12. Murgo AJ: Modulation of murine melanoma growth by naloxone. Cancer Lett 44: 137142, 1989.
13. Lewis JW, Shavit Y, Terman GW, Nelson LR Gale RP and Liebeskind JC: Apparent involvement of opioid peptides in stress-induced enhancement of tumor growth. Peptides 4: 635-638, 1983.
14. Zagon IS and McLaughlin PJ: Duration of opiate receptor blockade determines tumorigenic response in mice with neuroblastoma: a role for endogenous opioid system in cancer. Life Sci 35: 409-416, 1984.
15. Aylsworth CF, Hodson CA and Meites J: Opiate antagonists can inhibit mammary tumor growth in rats. Proc Soc Exp Biol Med 161: 18-20, 1979.
16. Maneckjee R, Biswas R and Vonderhaar BK: Binding of opioids to human MCF-7 breast cancer cells and their effects on growth. Cancer Res 50: 2234-2238, 1990.
17. Scholar EM, Violi L and Hexum TD: The antimetastatic activity of enkephalin-like peptides. Cancer Lett 35: 133-138, 1987.
18. Murgo AJ: Inhibition of B16-BL6 melanoma growth in mlce by methionineenkephalin. J Natl Cancer Inst 75: 341-344, 1985.
19. Tejwani GA, Gudehithlu KP, Hanissian SH, Gienapp IE, Whitacre CC and Malarkey WB: Facilitation of dimethylbenz(a)anthracene-induced rat mammary tumorigenesis by restraint stress: role of ß-endorphin, prolactin and naltrexone. Carcinogenesis 12: 637-641, 1911.
20. Abou-lssa H and Tejwani GA: Antitumor activity of naltrexone and correlation with steroid hormone receptors. Biochem Biophys Res Commun 175: 625 630, 1941.
21. Webb TE, Abou-lssa H, Dwiredi C and Koolemans-Beynen A: Synergism between glucarate and retinoids in the rat mammary system. In: Cancer Chemoprevention (Wattenberg M, Lipkin M, Boone CW and Kelloff G. eds). Boca Raton, FL., CRC Press, 1992, pp 263-277.
22. Sharma SK, Nirenberg M and Klee WA: Morphine receptors as regulators of adenylate cyclase activity. Proc Nat Acad Sci USA 72: 590-594, 1975.
23. Sharma SK, Klee WA and Nirenberg M: Opiate-dependent modulation of adenylate cyclase. Proc Nat Acad Sci USA 74: 3365-3369, 1977.
24. Ryan WL and Heidrick ML: Inhibition of cell growth in vitro by adenosine 3'.5'-monophosphate. Sci 162: 1484-1485, 1968.
25. Otten J, Johnson GS and Pastan I: Cyclic AMP levels in fibroblasts: relationship to growth rate and contact inhibition of growth. Biochem Biophys Res Commwn 44: 1192-1198, 1971.
26. Sheppard JR: Difference in the cyclic adenosine 3', 5'-monphosphate levels in normal and transformed cells. Nature-New Biol 23: 1416, 1972.
27. Johnson GS and Pastan I: Role of 3', 5'-adenosine monophosphate in regulation of morphology and growth of transformed and normal fibroblasts. J Natl Cancer Inst 48: 1377-1387, 1972.
28. Van Wijk R, Wicks WD and Clay K: Effects of derivatives of cyclic 3', 5'-adenosine monophosphate on the growth, morphology and gene expression of hepatoma cells in culture. Cancer Res 32: 1905- 1911, 1972.
29. Cho-Chung YS and Clair T: The role of cAMP on neoplastic cell growth and regression. Biochem Biophys Res Commun 64: 768-772, 1975.
30. Cho-Chung YS: Cyclic AMP and mammary tumor regression. Cell Mol Biol 26: 395-403, 1979.
31. Peyrat JP, Djiane J and Bonneterre J: Stimulation of DNA synthesis by prolactin in human breast tumor explants. Relation to prolactin receptors. Anticancer Res 4: 275-281, 1984.
32. Biswas R and Vonderhaar BK: Anti-estrogen inhibition of prolactin induced growth of the Nb2 rat lymphoma cell line. Cancer Res 49: 6295-6299, 1989.
33. Simon WE, Albrecht M and Trams G: In vitro growth promotion of human mammary carcinoma cells by steroid hormones, tamoxifen and prolactin. J Natl Cancer Inst 73: 313-321, 1984.
34. Manni A, Wright C, Davis G, Glenn J, Joehl R and Feil P: Promotion by prolactin of the growth of human breast neoplasms cultured in vitro in the soft agar clonogenic assay. Cancer Res 46: 1669-1672, 1986.
35. Grandison L and Guidotti A: Regulation of prolactin release by endogenous opiates. Nature 270: 357-359, 1977.
36. Rivier C, Vale W, Ling N, Brown M and Guillemin R: Stimulation in vivo of the secretion of prolactin and growth hormone by ß-endorphin. Endocrinol 100: 238-241, 1977.
37. Lien EL, Fenichel RL, Garsky V, Sarantakis D and Grant NH: Enkephalin-stimulated prolactin release. Life Sci 19: 837-840, 1976.
38. Bruni JF, Van Vugt D, Marshall S and Meites J: Effect of naloxone, morphine and methionine enkephalin on serum prolactin, luteinizing hormone, follicle stimulating hormone, thyroid stimulating hormone and growth hormone. Life Sci 2: 461-466, 1977.
39. Matton A, Buydens P, Finne E, Govaerts J and Vanhaelst L: Analysis of the receptor specificity of tolerance induction in stress versus opioid-related prolactin secretion in rats. J of Endocrinol 128: 281-285, 1991.
40. Cohen ND and Hilf R: Effect of estrogen treatment on DMBA-induced mammary tumor growth and biochemistry in intact and diabetic rats. Proc Soc Exp Biol Med 148: 339-343, 1975.
41. Leung BS and Sasaki GH: On the mechanism of prolactin and estrogen action in 7,12 dimethylbenz(a)anthracene-induced mammary carcinoma in the rat. II. In vitro tumor responses and estrogen receptor. Endocrinol 97: 564-572, 1975.
42. Sinha D, Cooper D and Dao TL: The nature of estrogen and prolactin effect on mammary tumorigenesis. Cancer Res 33: 411-414, 1973.
43. Meites J, Cassell E and Clark J: Estrogen inhibition of mammary tumor growth in rats; counteraction by prolactin, Proc Soc Exp Biol Med 137: 1225-1227, 1971.
44. Pearson OH, l,lerena O, l,lerena 1, Molina A and Butler T: Prolactin-dependent rat mammary cancer: a model for man? Trans Assoc Am Physicians 82: 225-238, 1969.
45. Blake CA, Norman RL and Sawyer CH: Effect of estrogen and-or progesterone on serum and pituitary gonadotropin levels in ovariectomized rats. Proc Soc Exp Biol Med 141: 1100-1103, 1972.
46. Ahmed HH, Van Vugt DA, Ruiz de Galarreta CM, Fanjul LF and Meites J: Naltrexone partially inhibits the estrogen-induced increase in prolactin secretion and anterior pituitary weight. Life Sci 29: 2757-2762, 1981.
47. Bonneterre J, Peyrat J PH, Beuscart R and Demaille A: Correlation between prolactin receptors (PRL R), estradiol (ER) and progesterone receptors (PgR) in human breast cancer. Eur J Cancer Clin Oncol 22: 1331-1336, 1986.
48. Pasqualini C, Sarrieau A, Dussaillant M, Corbani M, Bojda-Diolez F, Rostene W and Kerdelhue B: Estrogen-like effects of 7,12-dimethylbenz(a)anthracene on the female rat hypothalamo-pituitary axis. J Steroid Biochem 36: 485-491, 1990.
49. Garcia-Segura LM, Diolez-Bojda F, Lenoir V, Naftolin F and Kerdelhue B: Estrogenlike effects of the mammary carcinogen 7,12-dimethylbenz(alpha)anthracene on hypothalamic neuronal membranes. Brain Res Bull 28: 625-628, 1992.
50. Tempel A, Gardner EL and Zukin RS: Visualization of opiate receptor up-regulation by light microscopy autoradiography. Proc Natl Acad Sci USA 81: 3893-3897, 1984.
51. Tempel A, Kessler JA and Zukin RS: Chronic naltrexone treatment increases expression of preproenkephalin and preprotachykinin mRNA in discrete brain regions. J of Neurosci 10: 741-747, 1990.
52. Zagon IS and McLaughlin PJ: Opioid antagonist modulation of murine neuroblastoma: a profile of cell proliferation and opioid peptides and receptors. Brain Res 480: 16-28, 1989.